Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Hemostemix Inc

HEM.V ✓ COMPLIANT ☆ Track — members

TSX · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: N/A

Last Close

$0.05

▲ +7.14%

Market Cap $11.43M · Vol 21.80K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$11.43M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

50.00

Momentum

Beta

0.64

vs Market

52W High

$0.09

39.78% below

52W Low

$0.03

86.72% above

Volume

21.80K

Avg 20.59K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

83.37%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Hemostemix Inc (HEM.V) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HEM.V pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

+15.38%

+36.36%

-6.25%

YTD

-16.67%

-34.78%

-41.62%

-64.29%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-3,434,808.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-512.73% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	211.44M

Technical Indicators

50-Day SMA	$0.05
200-Day SMA	$0.05
RSI (14)	50.00
Beta	0.64
52-Week High	$0.09
52-Week Low	$0.03

Volume Today	21.80K
Avg Daily Volume (30D)	20.59K
Relative Volume	1.06x
Volatility (10D)	75.48
Volatility (30D)	87.76
Free Float	83.37%

Analyst Consensus

N/A

Current Price $0.05

Mean Target N/A

52W Low$0.03 52W High$0.09

Current

Target

$0.03 $0.09

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX

FIGIBBG0038N5RX3

ISINCA4236943060

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +4.82% ARGX.BR argenx SE +1.64% ARGX argenx SE +0.62% INSM Insmed Incorporated -3.18% 2269.HK WuXi Biologics (Cayman) Inc. +4.55%

Company Profile

Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.